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ABSTRACT  
Objective: Depression and anxiety are highly prevalent in patients with cardiovascular 
disease (CVD), and influence their mental wellbeing and CVD prognosis. The primary 
objective was to assess the effectiveness of cognitive behavioral therapy (CBT) for 
depression and anxiety in patients with CVD. Secondary objectives were to assess the impact 
of CBT on cardiovascular mortality, cardiovascular events, patient satisfaction and quality of 
life (QoL). 
Methods: MEDLINE, PsycINFO, CINAHL, CENTRAL, and alternative sources, were 
searched for randomized controlled trials (RCTs) and observational studies with a control. 
Studies were required to assess CBT in coronary heart disease, acute coronary syndrome, 
atrial fibrillation or post-myocardial infarction patients, with anxiety and/or depression. 
Studies were independently screened by two reviewers and critically appraised using the 
Cochrane Risk of Bias tool. The random effects model was used to pool standardized mean 
differences.   
Results: Twelve RCTs were included. At follow-up, depression (SMD -0.35, 95% CI -0.52 
to -0.17, p< 0.001, I
2
= 59%) and anxiety (SMD -0.34, 95% CI -0.65 to -0.03, p= 0.03, I
2
= 
71%) scores were significantly lower in CBT patients compared to controls. Change in 
mental health QoL (SF-12) was also significantly greater for CBT patients, compared to 
controls (MD 3.62, 95% CI 0.22 to 7.02, p= 0.04, I
2
= 0%). No differences in patient 
satisfaction or cardiovascular events were evident between CBT and control groups. Among 
the study reports included in this meta-analysis, data specific to cardiovascular mortality were 
not reported.  
Conclusions: CBT appears to be an effective treatment for reducing depression and anxiety 
in patients  with CVD and should be considered in standard clinical care. 
 
Key words: Cognitive behavioral therapy; Depression; Anxiety; Cardiovascular disease; 
Systematic review; Meta-analysis  
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Acronyms: 
ACS= acute coronary syndrome, AF= atrial fibrillation, CABG= coronary artery bypass 
grafting, CBT= cognitive behavioral therapy, CENTRAL= Cochrane Central Register of 
Controlled Trials, CHD= coronary heart disease, CI= confidence interval, CVD= 
cardiovascular disease, DSM= Diagnostic and Statistical Manual of Mental Disorders, 
GRADE= Grading of Recommendations Assessment, Development and Evaluation, ICD= 
implantable cardioverter defibrillator, MI= myocardial infarction, NICE= The National 
Institute for Health and Care Excellence, PRISMA= Preferred Reporting Items for 
Systematic Reviews and Meta-analyses, QoL= quality of life, RCT= randomized controlled 
trial, RoB= risk of bias. 
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INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide and responsible 
for almost one third of all deaths (1). European guidelines recognize depression and anxiety 
as important factors that contribute to the risk of developing CVD and a worse CVD 
prognosis, however the relationship between mental illness and CVD has received less 
recognition globally (2). Mechanisms linking anxiety and depression with CVD are 
unconfirmed however, biological and behavioral processes have been proposed (3,4). Both 
anxiety and depression have been implicated in the dysfunctional activity of the autonomic 
nervous system and hypothalamic-pituitary-adrenal axis which affect the cardiovascular 
system (3,4). Poor lifestyle behaviors such as smoking, inactivity and low treatment 
adherence which increase the CVD risk are also common in anxious and depressed patients 
(4). 
Prevalence of depression and anxiety among CVD patients is up to 3-fold higher than in the 
general population (5,6). Changes in quality of life (QoL) and the impact of a chronic disease 
can significantly affect mental wellbeing. Among coronary heart disease (CHD) patients, 
approximately 20% meet the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
criteria for major depression, and this can impact on disease outcomes (7). Depressed CVD 
patients experience a 2-fold increased risk of associated cardiovascular events and mortality 
(8). After a cardiovascular event, patients often experience anxiety which remains unresolved 
for 50% of patients throughout the following year (9). Anxiety and depression commonly co-
occur however the prognostic implications of suffering with both conditions are worse, 
resulting in a 3-fold increased risk of mortality (10). Therefore, treating depression and 
anxiety within CVD groups is important for both their mental wellbeing and CVD outcomes.   
Cognitive behavioral therapy (CBT) is currently recommended as the first-line treatment for 
anxiety (11) and depression (12) by the National Institute for Health and Care Excellence 
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(NICE) in the United Kingdom. During CBT, patients learn to monitor and improve their 
psychological wellbeing by recognizing and challenging unhelpful thinking patterns. 
Implementing different behaviors and thinking patterns, identified with the therapist, is 
integral to overcoming the negative emotions (13). CBT adopts a range of strategies that alter 
factors which maintain, trigger and exacerbate symptoms thus having the potential to increase 
adherence to medications and cardiac rehabilitation programmes (13,14). 
Current systematic reviews investigating the effectiveness of CBT are limited to patients with 
implantable cardioverter defibrillators (ICD), which report 20-60% reductions in depressive 
and anxious symptoms after CBT (15), and heart failure patients which found that CBT 
improved both anxious and depressive symptoms, and cardiac event survival (16,17). These 
findings however, should be interpreted with caution as few studies were included, 
interventions were mixed (e.g. CBT +/- an additional intervention), and lengths of follow-up 
differed. Further systematic reviews with meta-analyses have also found significantly 
improved anxious and depressive symptoms in CHD patients receiving various (non-CBT 
specific) psychological interventions (18-20).  
The effectiveness of CBT has not been assessed in CHD, acute coronary syndrome (ACS), 
atrial fibrillation (AF) and post-myocardial infarction (MI) patients, and the management of 
anxiety in CVD patients has also received less research focus (3). Therefore, this systematic 
review will assess the effectiveness of CBT for depression and/or anxiety in patients with 
CVD (CHD, ACS, AF or post-MI) and investigate the effects of CBT on cardiovascular 
events, cardiovascular mortality, patient satisfaction and QoL.  
METHODS 
This systematic review and meta-analysis was prospectively registered with the PROSPERO 
database of systematic reviews (CRD42017057723) (21), and conducted in accordance with 
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the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
guidelines (22).  
 
Criteria for considering studies for the review 
Randomized controlled trials (RCTs) and observational studies with a concurrent control 
group were eligible for inclusion. Studies were required to have a baseline and at least one 
follow-up measure for depression and/or anxiety. Access to the full-text publication was a 
requirement. There were no date or language restrictions.  
Participants 
Eligible participants were those with CVD (CHD, ACS, AF or post-MI) and depression or 
anxiety. Anxiety or depression was defined as either a clinical diagnosis (International 
Classification of Diseases (23), DSM (24), or similar) or the presence of anxious and/or 
depressive symptoms (≥ a pre-defined cut-off on a validated questionnaire). Studies of ICD 
and heart failure patients were excluded as recent previous systematic reviews have assessed 
the effectiveness of CBT for depression and/or anxiety in these patients (15,17). 
Interventions 
Interventions described as CBT or based on CBT principles were eligible for inclusion, where 
patients were taught to monitor their mood by identifying and challenging the thoughts and 
behaviors at the source of their depressive or anxious state. This could have been referred to 
as CBT, cognitive therapy or behavioral therapy. However, interventions that solely used the 
principles of cognitive therapy or behavioral therapy alone were excluded. „Third wave‟ CBT 
was also excluded because some forms only focus on one traditional CBT principle. Other 
psychotherapies (e.g. cognitive analytical therapy, psychodynamic psychotherapy and 
interpersonal psychotherapy) were excluded. Studies that investigated CBT as one element 
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within a mixed intervention package were not included, although CBT with an adjunctive 
antidepressant as recommended by NICE was accepted (12).  
 
Comparators 
Eligible comparators were medications, usual care (including other psychological therapies), 
waiting list control or no treatment. 
Outcomes 
The primary outcome was a reduction in anxiety and/or depression in CVD patients 
following CBT. Patients still classified as depressed and/or anxious according to a validated 
questionnaire and those no longer meeting the clinical diagnosis at follow-up were also 
reported. Secondary outcomes included: cardiovascular events, cardiovascular mortality, 
patient satisfaction and QoL.  
Search Strategy 
The search strategy was developed by the research team and checked by an information 
specialist prior to execution (see Supplementary Figure S1, Supplemental Digital Content, 
http://links.lww.com/PSYMED/A498). Key words such as „CBT‟, „Heart diseases‟, 
„Anxiety‟ and „Depression‟ were used. MEDLINE, PsycINFO, CINAHL and the Cochrane 
Central Register of Controlled Trials (CENTRAL) were searched from inception to 10th 
February 2017 for relevant studies. No language restrictions were applied.  
Reference lists of included studies were manually searched and citation searches were 
completed to identify other relevant articles. Grey literature was addressed by contacting the 
leading authors of included papers and key opinion leaders for unpublished data. 
Clinicaltrials.gov was searched for unpublished protocols of RCTs from 2007-2017. 
Conference proceedings of the European Society of Cardiology, American Heart Association 
and American College of Cardiology 2015-2017 were also searched.  
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Study Selection 
Study selection was undertaken by two independent reviewers (JR, MH). Papers with 
irrelevant titles and abstracts were excluded and those deemed eligible or unclear were 
further assessed in their full-texts. Original authors were contacted for additional information 
when necessary for eligibility assessments. Disagreements over study eligibility were 
resolved by discussion and adjudication by a third reviewer (DL).  
Data Extraction 
Using a standardized, pre-piloted data extraction form, data were extracted by one reviewer 
(JR), with 25% checked by another reviewer (MH). Information regarding the study 
characteristics (study design, and sample size), participants (age, sex, psychiatric assessment, 
and CVD diagnosis), intervention (mode of delivery, duration, frequency, providers, and 
follow-up points) and comparator were gathered. For the primary outcome, mean differences 
and standard deviations for anxiety and depression scores between baseline and follow-up 
and the proportion still classified as depressed and/or anxious at follow-up were extracted. 
The proportion no longer meeting the clinical diagnosis for anxiety and/or depression at 
follow-up was noted. For the secondary outcomes, the proportions of patients experiencing 
cardiovascular events and death were collected in addition to mean differences and standard 
deviations for patient satisfaction (on a Likert scale) and QoL (on a validated questionnaire) 
between baseline and follow-up.  
Original authors were contacted when information was unclear or missing. If changes in 
scores between baseline and follow-up were unavailable and could not be imputed, follow-up 
scores were used as an alternative outcome. Only findings reported post-CBT were extracted. 
Four authors (25-28) were contacted for missing standard deviations, however only one 
author provided this data (27). Six authors provided data on an eligible study subgroup of 
their population (29-34). 
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Risk of Bias Assessment 
Two reviewers independently assessed the risk of bias (RoB) using the Cochrane RoB tool 
(35) for RCTs (all included studies were RCTs), consisting of six domains: random sequence 
generation; allocation concealment; blinding of participants, personnel and outcome 
assessors; selective reporting; and other sources of bias. RoB was assigned as „high‟, „low‟ or 
„unclear‟ for each domain.  
Data Synthesis 
For anxiety, depression, patient satisfaction and QoL outcomes, attempts were made to report 
change from baseline scores. If this data were not reported and could not be provided by 
study authors, imputation was attempted. However, the correlation coefficients calculated for 
anxiety, depression, and QoL were ≤0.5 or were too different to average and therefore, 
follow-up scores were used as an alternative outcome, as recommended by Cochrane (36). 
Standardized mean differences and 95% confidence intervals (CIs) were calculated for 
continuous outcomes when data were measured using different scales. When outcomes were 
measured using the same scales, mean differences and 95% CIs were calculated. The 
proportions experiencing continued depression and/or anxiety (according to a validated 
questionnaire), cardiovascular death, cardiovascular event(s), and those no longer meeting a 
clinical diagnosis of depression and/or anxiety at follow-up were each summarized with odds 
ratios and 95% CIs.  
Effect estimates were pooled using RevMan 5.3. DerSimonian and Laird random-effects 
method (36) was employed when outcome scales differed between studies and standardized 
mean differences were used; when outcomes used the same scales in analyses, the fixed 
effects model was employed when pooling mean differences. Heterogeneity was assessed by 
observing the overlap of confidence intervals on the forest plots and the I
2
 value, with meta-
analysis deemed inappropriate if there was considerable heterogeneity (I
2
 ≥75%) (36). 
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When studies had multiple trial arms, the CBT intervention was compared to usual care. If 
outcomes were measured at different time-points, the first outcome measure reported post-
CBT was used in the meta-analysis. If studies reported multiple depression scores from 
different scales, the most common scale used by other eligible studies was chosen when 
pooling effect estimates to minimize heterogeneity. 
Publication Bias 
Publication bias was assessed using a funnel plot and Egger‟s test when outcomes included 
≥10 studies. 
Risk of Bias across Studies (Quality Assessment) 
Quality of the outcomes was assessed using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) considerations (37).  
Subgroup Analyses 
Pre-specified subgroup analyses were conducted for each CVD (e.g., CHD, AF, etc.) where 
data were available, the mode of CBT delivery, and different lengths of follow-up. Study data 
on post-coronary artery bypass grafting (CABG) participants were included within the CHD 
subgroup analysis (a CHD history was assumed). Subgroup analyses for the mode of delivery 
(face-to-face, telephone and mixed-method sessions), length of CBT course (short: 0-300 
minutes, medium: 301-600 minutes, and long: >600 minutes), and length of follow-up (short-
term: baseline to ≤3 months, medium-term: >3 months but ≤6 months, and long-term: >6 
months) were completed.  
Sensitivity Analyses 
Sensitivity analyses were undertaken for studies with clinically diagnosed anxiety and/or 
depression versus no clinical diagnosis, and for the primary outcomes excluding studies with 
a high RoB. A sensitivity analysis comparing RCTs versus observational studies was planned 
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but all included studies were RCTs. Further sensitivity analyses were completed for all 
studies vs no US trials, and all studies vs no ENRICHD trial. 
 
RESULTS 
Study Selection 
Searches identified 2115 articles (Figure 1). After the removal of duplicates (n=141), the 
titles and abstracts of 1974 papers were independently assessed for eligibility by two 
reviewers. Of these, 117 papers were deemed potentially relevant and assessed for eligibility 
in their full-texts; 107 articles were excluded and 2 studies were ongoing (CBT-AF 
(ISRCTN33129243) (38) and U-CARE Heart trial (NCT01504191) (39)). Reviewers‟ 
agreement was 96.7%. Twelve papers were included, of which 2 were identified from 
reference lists of included studies (28,31) and 2 through citation searches (26,32).  
Characteristics of the Included Studies 
All included studies were RCTs and in English, conducted in the US (n=7) (26-32), Germany 
(n=2) (25,40), Australia (n=2) (33,41), and the UK (n=1) (34), (Table 1). 
Participants 
Participants were CHD (6 studies) (25-27,32,34,40), ACS (4 studies) (28,30,31,41) or post-
MI (1 study) (29) patients, and 1 study was a mixed CVD group (33). Studies recruited 
participants based on anxiety and/or depression (3 studies) (26,28,34), depression alone (8 
studies) (25,27,29-33,41), or anxiety alone (1 study) (40). Eight studies recruited participants 
using a validated questionnaire (26, 28,30,31,33,34,40,41), 1 used a formal clinical diagnosis 
(29) and 3 used a combination (25,27,32). Participants tended to be male (38.5-87.5%), over 
60 years (mean= 55.6-64.2 years), and of white ethnicity. Study sample sizes ranged from 43 
to 1332 participants. 
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Interventions 
CBT was the named intervention in 8 studies (25-29,32,33,41), and 4 studies described 
interventions based on CBT principles (30,31,34,40). Adjunctive antidepressants were 
offered in 3 studies (29-31). CBT was delivered through face-to-face (7 studies) (25-
27,29,32,33,40), mixed-method (3 studies) (30,31,34) or telephone (2 studies) (28,41) 
sessions; all studies delivered ≥4 sessions. CBT was provided by psychologists (5 studies) 
(26,28,33,40,41), psychotherapists (3 studies) (25,29,31), mixed groups of healthcare 
professionals (2 studies) (27,30), and trained nurses (2 studies) (32,34). 
Comparator 
All comparators were usual/standard care, except in 2 studies which either provided a brief 
intervention of information and feedback on baseline assessments (also received by the 
intervention group) or no intervention (33,40). Studies described usual care as dependent on 
the patient‟s primary care physician (30-32,41) and standard care involved identification of 
risk factors and advice on risk reduction (34), or booklets on coping with CVD (28).  
Outcomes 
Baseline and follow-up scores for anxiety were available in 9 studies (25-28,31-34,40) and 
depression in 12 studies (25-34,40,41). Four depression scales and 5 anxiety scales were used 
at various time-points (1-12 months) to measure depression and anxiety (Table 2). Four 
studies reported the proportion of participants achieving remission of depression at follow-
up; the proportion still depressed at follow-up was calculated (27,31-33). One study reported 
the proportion of participants no longer meeting a clinical diagnosis of depression at follow-
up (32). No studies published cardiovascular mortality data for participants eligible for 
inclusion in this review; however, 2 studies recorded cardiovascular events (nonfatal MI or 
hospitalization for unstable angina) (30,31). Two studies reported changes in patient 
satisfaction between baseline and follow-up (30,34). Participant QoL was available in 5 
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studies (26,27,31,34,41) and was assessed as physical or mental QoL (SF-12) separately, or 
the sum of the QoL.  
Risk of Bias within Studies 
Due to the nature of CBT all studies had a high RoB for personnel and participant blinding. 
Of the 12 included studies, a high RoB was assigned to 3 for incomplete outcome data 
(25,28,40), 2 for other biases (28,29) and 1 for selective reporting (29) (Figure 2). An unclear 
RoB was assigned to 4 studies for allocation concealment (26,28,32,40), and to 6 studies 
(25,26,28,32-34) for selective reporting as protocols were unavailable.  
Sensitivity analyses of the primary outcomes were conducted for studies without a high RoB 
for the following domains: blinding of outcome assessment, incomplete outcome data, 
selective reporting and other bias. The domains listed were those with studies rated at a high 
RoB. Sensitivity analyses demonstrated the inclusion of studies with a high RoB did not 
significantly influence the primary outcomes (data not shown). 
Effectiveness of CBT for Depression and Anxiety 
The pooled depression follow-up scores from all 12 studies included 2254 participants (25-
34,40,41). Depression follow-up scores were significantly lower in CBT patients than in 
controls (SMD -0.35, 95% CI -0.52 to -0.17, p< 0.001, I
2
= 59%) (Figure 3A). Compared to 
controls, fewer CBT participants remained depressed after the intervention (OR 0.29, 95% CI 
0.12 to 0.69, p= 0.005, I
2
= 62%) (Figure 3B). One study reporting the proportion of 
participants no longer meeting a clinical diagnosis of depression found the CBT group had 
significantly fewer participants (31%) no longer meeting the diagnosis for depression 
compared to the controls (83%) (OR 0.10, 95% CI 0.03 to 0.36, p< 0.001) (32). 
The pooled anxiety follow-up scores from 9 studies included 605 participants (25-28,31-
34,41). Anxiety was significantly lower in CBT patients than in controls however, substantial 
heterogeneity was present (SMD -0.34, 95% CI -0.65 to -0.03, p= 0.03, I
2
= 71%) (Figure 4).  
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Cardiovascular mortality 
No studies published cardiovascular mortality data for depressed or anxious CVD patients. 
One trial had subgroup data for depressed only CVD patients, but this was not accessible to 
the authors for inclusion in this review (29). 
Cardiovascular events 
Two studies including 260 participants reported cardiovascular events (30,31). The pooled 
scores showed fewer cardiovascular events in CBT patients compared to the controls 
however, this was not statistically significant (OR 0.80, 95% CI 0.33 to 1.93, p= 0.62, I
2
= 
0%). 
Patient satisfaction 
Two studies (130 participants) provided a change in patient satisfaction between baseline and 
follow-up (30,34). Pooled scores demonstrated greater patient satisfaction in favor of CBT 
compared to controls however, this was not statistically significant (SMD 0.11, 95% CI -0.29 
to 0.51, p= 0.28, I
2
= 16%). 
Quality of Life 
A non-significant difference between the CBT and control groups was observed for the 
change in physical health QoL (SF-12) (MD 2.59, 95% CI -0.41 to 5.60, p= 0.09, I
2
= 0%) 
however, the change in mental health QoL (SF-12) was significantly better in CBT patients 
compared to controls (MD 3.62, 95% CI 0.22 to 7.02, p= 0.04, I
2
= 0%). Overall QoL at 
follow-up was greater in CBT patients compared to controls but this was not significant 
(SMD -0.10, 95% CI -0.47 to 0.26, p= 0.58, I
2
= 47%). 
Publication Bias 
A visual assessment of the funnel plot for depression follow-up highlighted little asymmetry 
(see Supplementary Figure S2, Supplemental Digital Content, 
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http://links.lww.com/PSYMED/A498). The Egger‟s test for publication bias was not 
significant (0.034, 95% CI -1.82 to 1.89, p= 0.97). 
Risk of Bias across Studies (Quality Assessment) 
Using the GRADE considerations, the quality of the primary and secondary outcomes was 
reported as either „low‟ or „very low‟ within a Summary of Findings table (see 
Supplementary Table S3, Supplemental Digital Content, 
http://links.lww.com/PSYMED/A498).  
Subgroup Analyses 
A subgroup analysis conducted for CHD participants found a smaller proportion of those 
receiving CBT were still classified as depressed at follow-up, compared to controls (OR 0.14, 
95% CI 0.06 to 0.30, p< 0.001, I
2
= 0%), however, anxiety and depression follow-up scores 
demonstrated considerable heterogeneity (I
2  
≥75%) so pooling was deemed inappropriate.  
There was insufficient data for subgroup analyses of the secondary outcomes. 
A significant difference in depression at follow-up (SMD -0.29, 95% CI -0.48 to -0.09, p= 
0.003, I
2
= 4%) was observed in ACS patients receiving CBT but not for anxiety (SMD -0.16, 
95% CI -0.48 to 0.16, p=0.34, I
2
= 0%).  
There was a significant reduction in depression at follow-up between CBT and control 
patients after face-to-face sessions (SMD -0.48, 95% CI -0.73 to -0.23, p< 0.001, I
2
= 60%) 
but not following telephone (SMD -0.17, 95% CI -0.57 to 0.23, p= 0.40, I
2
= 49%) or mixed-
method (SMD -0.19, 95% CI -0.56 to 0.18, p= 0.32, I
2
= 66%) sessions. Anxiety was only 
significantly reduced following face-to-face CBT (SMD -0.48, 95% CI -0.90 to -0.07, p= 
0.02, I
2
= 73%).  
Depression and anxiety were significantly reduced in patients receiving CBT at short-term 
(SMD -0.47, 95% CI -0.84 to -0.10, p= 0.01, I
2
= 69% for depression; SMD -0.44, 95% CI -
0.88 to 0.01, p= 0.05, I
2
= 77% for anxiety) and medium-term follow-up (SMD -0.26, 95% CI 
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-0.39 to -0.12, p< 0.001, I
2
= 28% for depression; SMD -0.26, 95% CI -0.46 to -0.06, p= 0.01, 
I
2
= 3% for anxiety),  but not at long-term follow-up (SMD -0.37, 95% CI -1.12 to 0.38, p= 
0.34, I
2
= 72% for depression; SMD -0.46, 95% CI -0.83 to -0.10, p= 0.01, I
2
= 0% for 
anxiety) compared to controls.  
A significant reduction in anxiety was seen in long CBT courses (SMD -0.42, 9%% CI -0.77 
to -0.08, p= 0.02, I
2
= 0%) but not in short or medium courses (SMD -0.33, 95% CI -1.01 to 
0.35, p= 0.34, I
2
= 88%; SMD -0.30, 95% CI -0.63 to 0.02, p=0.07, I
2
= 0%), compared to 
controls. A significant reduction in depression was seen in medium CBT courses (SMD -
0.35, 95% CI -0.45 to -0.26, p<0.001, I
2
= 0%) but not for short or long courses (SMD -0.23, 
95% CI -0.72 to 0.26, p=0.36, I
2
= 79%; SMD -0.55, 95% CI -1.40 to 0.30, p=0.20, I
2
= 82%), 
compared to controls.  
Sensitivity Analysis 
Removal of participants with clinically diagnosed depression (29) did not significantly alter 
the primary outcomes (depression: SMD -0.34, 95% CI -0.56 to -0.12, p= 0.002; anxiety: 
SMD -0.34, 95% CI -0.65 to -0.03, p= 0.03; proportion remaining depressed: OR 0.29, 95% 
CI 0.12 to 0.69, p= 0.005). 
Depression and anxiety at follow-up were attenuated and became non-significant when the 
US trials were excluded from the analyses (SMD -0.12, 95% CI -0.36 to 0.13, p= 0.36, I
2
= 
25%; SMD -0.12, 95% CI -0.38 to 0.15, p= 0.38, I
2
= 0%). Removal of the ENRICHD trial 
(29), resulted in a marginal change in depression at follow-up and it remained significant 
(SMD -0.34, 95% CI -0.56 to -0.12, p= 0.002, I
2
= 63%).  
DISCUSSION 
This is the first systematic review and meta-analysis to specifically investigate the 
effectiveness of CBT for anxiety and depression in CHD, ACS, AF and post-MI patients. 
CBT significantly reduced both depression and anxiety, and improved QoL compared to 
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controls. However, substantial heterogeneity was present in the pooled anxiety follow-up 
scores so these results should be interpreted with caution. CBT also significantly reduced the 
proportion of patients still depressed at follow-up, when compared to controls. However, 
there were no significant differences between CBT and control patients regarding 
cardiovascular events or patient satisfaction. This may be partly attributable to the lack of 
available data for these outcomes. Compared to controls, face-to-face CBT was the only 
mode of delivery to demonstrate statistically significant differences in anxiety and 
depression. Depression and anxiety were significantly reduced at all follow-up points.  
With the known association between poor mental health and worse CVD outcomes (2), future 
studies should investigate the impact of CBT on cardiovascular mortality and events. A 
previous systematic review in CHD patients found a small but non-significant effect of 
psychological interventions in reducing cardiac mortality (RR 0.80, 95% CI 0.64 to 1.00, p= 
0.56, I
2
= 0%) (20). Previous reviews have also demonstrated beneficial effects of mixed 
psychological interventions in depressed CHD patients (18-20). Greater reductions in 
depression have been demonstrated in this review, and may indicate the superiority of CBT to 
other psychological interventions. Unfortunately, other CVDs such as AF have received less 
research focus and only one included study recruited AF patients (33). An on-going trial is 
currently investigating the effectiveness of CBT in AF patients with depression and/or 
anxiety (38).  
The benefit of face-to-face CBT over other methods may indicate the importance of personal 
and interactive sessions, and this should be considered in future CBT trials. Internet-based 
CBT alone was not investigated by any included study so the individual effect could not be 
deduced. This method may provide a widely accessible and cheaper form of CBT although 
may not be suitable for moderate-to-severe depression or anxiety. No study has investigated 
the effectiveness of internet-based CBT in CVD patients (post-MI, CHD, ACS or AF) with 
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depression and/or anxiety. However, an on-going trial, examining the effectiveness of 
internet-based CBT in post-MI patients with depression and/or anxiety (39), may indicate any 
potential benefit of internet-based CBT in CVD patients. Interestingly, depression and 
anxiety at follow-up were attenuated and non-significant after the removal of the US trials. 
When interpreting this finding, it is important to remember that 7/12 trials included within 
this review were conducted in the US and therefore, US patients represent the largest 
proportion (84%). The sensitivity analysis suggests that the US trials are driving the positive 
findings of CBT on a reduction in depression and anxiety. There may be country-specific 
differences in the experiences of patients and/or delivery of CBT which influenced the results 
of these trials.  
Reductions in depression were greatest at short-term follow-up, thus suggesting longer CBT 
courses may be required to maintain psychological wellbeing post-intervention. Anxiety 
symptoms however, were most improved at long-term follow-up.  This could be explained by 
heightened anxiety regarding therapy completion, and concerns of less therapist contact (14). 
This review has numerous strengths. A range of databases were searched without restrictions 
on language or timescales, authors supplied subgroup data, and the study selection process 
and RoB assessments were conducted independently by two reviewers. However, there was 
considerable heterogeneity between study participants, outcome scales, CBT content and 
delivery, which may influence the findings.  
There are some limitations to this review. Within studies, blinding participants to CBT is 
challenging and can be problematic when outcomes are self-reported. The participant‟s 
knowledge of their allocation could influence their responses and introduce social desirability 
bias. Four studies (25,28,29,40) also had a high RoB for ≥1 of the remaining RoB tool 
domains. However, when assessed in a sensitivity analysis, removal of studies with a high 
RoB did not significantly affect the review‟s primary results. The review outcomes were 
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assessed by GRADE as low or very low quality which is partly attributable to the fact that the 
participants and personnel could not be blinded. However, other factors affecting outcome 
quality such as heterogeneity and differences in intervention delivery between studies could 
be overcome in future RCT trials by using similar outcome measures, methodology and 
intervention delivery. As this review has suggested, at least 5 hours of CBT is necessary to 
reduce anxiety and depression in CVD patients. Furthermore, long-term follow-up may be 
more valuable for identifying the effects of CBT on anxiety and depression. For some studies 
only a specific sample of their participants were relevant to this review, which consequently 
created smaller sample sizes. Furthermore, subgroup analysis data were not available from all 
the studies (29). Future RCTs should increase their sample sizes of CHD, ACS, AF and post-
MI patients in order to improve the quality of review outcomes.  
This review supports the use of CBT as a first-line treatment for anxiety and depression in 
CVD patients, as recommended by NICE (11,12). To maximize the benefit of this therapy, 
clinicians should prioritize face-to-face sessions and increase CBT duration. However, CBT 
is time-consuming and expensive, therefore other methods may be required. On-going 
research may demonstrate the benefits of internet-based sessions with the potential to lower 
CBT costs (39). Previous research suggests men and women with CHD respond differently to 
depression treatment (29). However, no review within this field has assessed the effects of 
CBT on depression or cardiovascular outcomes by gender. Due to lack of access to data 
separately for men and women in half of the studies included in this review, an analysis by 
gender was not possible however, future research should assess the gender differences in the 
effects of CBT and report findings by gender.  
In conclusion, this review and meta-analysis supports the effectiveness of CBT in reducing 
anxiety and depression and improving QoL in CVD patients, and indicates this therapy 
should be considered by clinicians. However, considerable heterogeneity was present 
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between studies and AF patients were poorly represented. Face-to-face CBT sessions appear 
to achieve the greatest patient benefit and this should be considered when designing future 
studies. Furthermore, it is essential that cardiovascular outcomes are recorded to develop our  
understanding of the impact of CBT on CVD prognoses. 
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Figure captions 
Figure 1: PRISMA flow diagram for the study selection process 
 
Figure 2: Risk of Bias Assessment for the Included Studies  
 
Figure 3A: Forest plot of depression follow-up scores 
 
Figure 3B: Forest plot of participants remaining depressed at follow-up 
 
Figure 4: Forest plot of anxiety follow-up scores 
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Figure 3b 
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Table 1: Characteristics of Included Studies 
First Author; Year; 
Country; Study 
Design 
Total number of participants 
randomized (n); Mean (SD) Age, 
years; % Male; % White Ethnicity 
CVD 
Diagnosis 
Anxiety 
and/or 
Depression 
Method of 
anxiety and/or 
depression 
diagnosis 
CBT intervention Comparator Outcomes (Modality used) 
Barth 2005 (25) 
Germany  
RCT 
 
 
 
Berkman 2003* (29) 
USA 
RCT 
 
Dao 2011 (26) 
USA 
RCT 
 
 
 
Davidson 2010* (30) 
USA 
RCT 
 
 
 
Davidson 2013* (31) 
USA 
RCT 
 
 
 
Doering 2013* (32) 
USA 
RCT 
 
 
 
 
Freedland 2009 (27) 
USA 
RCT 
n=59 
Intervention: 60.8 (11.1); 81.5%; 
† 
Comparator: 55.6 (10.1); 71.9%; 
† 
 
n=1332 
Intervention: †; †; †  
Comparator: †; †; † 
 
n=100 
Intervention: 62.8 (11.8); 77.1%; 
81.2% 
Comparator: 64.2 (11.9); 79.6%; 
77.6% 
 
n=150 
Intervention: 61.5 (10.7); 38.5%; 
52.0% 
Comparator: 61.1 (10.6); 46.8%: 
52.0% 
 
n=121 
Intervention: 60.3 (10.3); 56.8%; 
47.7% 
Comparator: 60.0 (11.1); 57.1%; 
54.5% 
 
n=55 
Intervention: 62.3 (7.7); 87.5%; 
56.3% 
Comparator: 63.0 (12.4); 60.9%; 
69.6% 
 
n=123 
Intervention: 62.0 (11.0); 44.0%; 
88.0% 
Comparator: 61.0 (9.0); 57.0%; 
90.0% 
CHD 
 
 
 
 
 
Post-MI 
 
 
 
CHD 
 
 
 
 
 
ACS 
 
 
 
 
 
ACS 
 
 
 
 
 
Post-
CABG 
 
 
 
 
 
Post-
CABG 
 
 
Depression 
 
 
 
 
 
Depression 
 
 
 
Anxiety 
and/or 
Depression 
 
 
 
Depression 
 
 
 
 
 
Depression 
 
 
 
 
 
Depression 
 
 
 
 
 
 
Depression 
 
 
HADS total ≥17 
and met DSM-IV 
depression 
criteria  
 
 
Met DSM-IV 
depression 
criteria  
 
STAI ≥40 on the 
State or Trait 
Scale. BDI-II ≥14 
 
 
 
BDI ≥ 10 on 2 
occasions 
 
 
 
 
BDI ≥10 on 2 
occasions or BDI 
>15 on 1 occasion 
 
 
 
BDI >10 and met 
DSM-IV 
depression 
criteria 
 
 
 
BDI ≥10 and met 
DSM-IV 
depression 
criteria  
Four to six, 50-minute, face-
to-face sessions, delivered by 
a psychotherapist. 
 
 
 
Six, 60-minute, face-to-face 
sessions, delivered by trained 
therapists. 
 
Four, 60-minute, face-to-face 
sessions, delivered by clinical 
psychologists. 
 
 
 
30-45 minute, face-to-face or 
telephone sessions, delivered 
by a specialist nurse, social 
worker or psychologist. Mean 
number of sessions= 8.2  
 
30-45 minute, internet and 
telephone sessions, delivered 
by problem-solving therapy 
specialists. Mean number of 
sessions= 7.7 
 
Eight, 50-60 minute, face-to-
face sessions, delivered by 
nurses. 
 
 
 
 
Twelve, 50-60 minute, face-
to-face sessions, delivered by 
clinical psychologists and 
social workers. 
 
Usual Care 
 
 
 
 
 
Usual Care 
 
 
 
Usual Care 
 
 
 
 
 
Usual Care 
 
 
 
 
 
Usual Care 
 
 
 
 
 
Usual Care 
 
 
 
 
 
 
Usual Care 
 
Depression (BDI) 
Anxiety (HADS-A) 
 
 
 
 
Depression (BDI) 
 
 
 
Depression (BDI-II) 
Anxiety (STAI-Trait) 
QoL (SF-12) 
 
 
 
Depression (BDI) 
Patient satisfaction (Likert scale) 
MACE 
 
 
 
Depression (BDI) 
Anxiety (PROMIS) 
Remission (BDI) 
QoL (SF-12) 
Cardiovascular events 
 
Depression (BDI) 
Anxiety (BSI) 
Remission (BDI, SCID) 
 
 
 
 
Depression (BDI) 
Anxiety (BAI) 
Remission (BDI) 
QoL (SF-36) 
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ACS, acute coronary syndrome; AF, atrial fibrillation; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory-II; BSI, Brief Symptom Inventory; CABG, 
coronary artery bypass grafting; CHD, coronary heart disease; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-IV; HADS, Hospital Anxiety and Depression Scale; HADS-A, 
Hospital Anxiety and Depression Scale-Anxiety Subscale; HADS-D, Hospital Anxiety and Depression Scale-Depression Subscale; MACE, nonfatal myocardial infarction or hospitalisation for 
unstable angina; MI, myocardial infarction; PCI, percutaneous coronary intervention; PHQ-9, Patient Health Questionnaire-9; PROMIS, Patient-Reported Outcomes Measurement Information 
System; QoL, quality of life; SAQ, Seattle Angina Questionnaire; SCID, Structured Clinical Interview for DSM-5; SD, standard deviation; SEIQoL-DW, Schedule for the Evaluation of Individual 
Quality of life: a Direct Weighting Procedure; SF-12, 12-Item Short Form Survey; SF-36, 36-Item Short Form Survey; STAI, State-Trait Anxiety Inventory; *, subgroup; †, not reported. 
First Author; Year; 
Country; Study Design 
Total number of 
participants randomized 
(n); Mean (SD) Age, 
years; % Male; % White 
Ethnicity 
CVD 
Diagnosis 
Anxiety 
and/or 
Depression 
Method of 
anxiety and/or 
depression 
diagnosis 
CBT intervention Comparator Outcomes (Modality used) 
McLaughlin 2005 (28) 
USA 
RCT 
 
 
 
 
Merswolken 2011 (40) 
Germany 
RCT 
 
 
 
O’Neil 2014 (41) 
Australia 
RCT 
 
 
 
Turner 2013* (33) 
Australia 
RCT 
 
 
 
 
Zetta 2011* (34) 
Scotland 
RCT 
n=100 
Intervention: 59.9 (10.2); 
68.9%; 88.9% 
Comparator: 60.7 (9.8); 
64.7%; 88.2% 
 
n=62 
Intervention: 62.5 (8.3); 
76.0%; † 
Comparator: 59.8 (7.5); 
70.0%; † 
 
n=121 
Intervention: 61.0 (10.2); 
73.8%; † 
Comparator: 58.9 (10.7); 
76.7%; † 
 
n=43 
Intervention: 61.6 (11.0); 
81.8%; † 
Comparator: 62.0 (9.0); 
71.4%; † 
 
 
n=98 
Intervention: 62.4 (10.2); 
68.2%; 97.7% 
Comparator: 61.8 (11.1); 
63.0%; 100% 
ACS 
 
 
 
 
 
CHD 
 
 
 
 
 
ACS 
 
 
 
 
 
AF, ACS, 
Post-CABG, 
Post-PCI  
 
 
 
 
CHD 
Anxiety 
and/or 
Depression 
 
 
 
Anxiety 
 
 
 
 
 
Depression 
 
 
 
 
 
Depression 
 
 
 
 
 
 
Anxiety 
and/or 
Depression  
 
HADS-A ≥7 or 
HADS-D ≥7 
 
 
 
 
HADS-A ≥8  
 
 
 
 
 
PHQ-9= 5-19 
 
 
 
 
 
BDI-II ≥14 
 
 
 
 
 
 
HADS-A ≥8 
and/or HADS-D 
≥8 
 
Six, 30-minute, telephone 
sessions, delivered by 
doctoral level clinicians. 
 
 
 
Twelve, 2-hour, face-to-face 
sessions, plus 3 additional 
booster sessions, delivered 
by clinical psychologists. 
 
 
Ten, 30-40 minute, telephone 
sessions, delivered by master 
level qualified psychologists. 
 
 
 
Six, 90-minute, face-to-face 
sessions (plus additional 120 
minutes), delivered by clinical 
psychologists. 
 
 
 
One, 45-minute, face-to-face 
session and three, 5-minute, 
telephone sessions delivered 
by nurses. 
 
Standard Care 
 
 
 
 
 
No 
intervention 
 
 
 
 
Usual Care 
 
 
 
 
Brief 
intervention 
of 
information  
  
 
 
Standard Care 
 
Depression (HADS-D) 
Anxiety (HADS-A) 
 
 
 
 
Depression (HADS-D) 
Anxiety (HADS-A) 
 
 
 
 
Depression (PHQ-9) 
QoL (SF-12) 
 
 
 
 
 
 
Depression (BDI-II) 
Anxiety (HADS-A) 
Remission (BDI-II) 
 
 
 
 
 
 
 
 
Depression (HADS-D) 
Anxiety (HADS-A) 
Patient satisfaction (SAQ) 
QoL (SEIQoL-DW) 
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